Stockscreener 앱 받기
7.53
1.76%
0.13
시간 외 거래:
7.53
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
BioCryst to Report First Quarter 2025 Financial Results on May 5 | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025 - Nasdaq
BioCryst to Report First Quarter 2025 Financial Results on May 5 - GlobeNewswire
BioCryst Earnings Preview: Key Financial Updates and Corporate Strategy Reveal Coming May 5 - Stock Titan
Where are the Opportunities in (BCRX) - news.stocktradersdaily.com
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st
BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry - TradingView
BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO - MSN
BioCryst appoints interim CFO following executive departure By Investing.com - Investing.com India
BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis - MarketScreener
Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting OfficerSEC Filing - marketscreener.com
BioCryst Appoints CEO as Interim CFO Amid Transition - TipRanks
BioCryst appoints interim CFO following executive departure - Investing.com
BioCryst at Needham Conference: Growth Amidst Competition By Investing.com - Investing.com India
BioCryst at Needham Conference: Growth Amidst Competition - Investing.com
(BCRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan
BioCryst to Present at Upcoming Investor Conference - The Manila Times
BioCryst Takes Center Stage: Key Updates Coming at Major Healthcare Conference - Stock Titan
Plasma Protease C1-inhibitor Market Size, Growth Report 2034 - Global Market Insights Inc.
Biocryst discovers new KLK5 inhibitors - BioWorld MedTech
BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews
North Carolina biotech sues to block copies of $400M drug - The Business Journals
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance
Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St
(BCRX) Technical Data - news.stocktradersdaily.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law News
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - biocentury.com
0.47%
0.69%
자본화:
|
볼륨(24시간):